← All trials
NCT05508867
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 18, 2022
- Primary completion
- Jun 16, 2031
- Completion date
- Jun 16, 2031
- First posted
- Aug 19, 2022
- Last posted
- Dec 6, 2022
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.